Intro

This chapter discusses Eli Lilly's successful trial results for its oral weight loss drug, forglopron, which has positively affected the company's stock. It also contrasts this with UnitedHealth's disappointing performance and the resulting decline in its shares amidst growing competitive pressures in the obesity drug market.